Stuart Cockerill
Senior Lecturer
School of Medicine, Pharmacy and Health
Durham University
United Kingdom
Biography
Stuart Cockerill is a Senior Lecturer in Medicinal Chemistry within the Pharmacy Division based at Queen’s Campus, Stockton. Stuart obtained his Ph.D. in Organic Chemistry at the University of Leeds working with Professor Philip Kocienski FRS. After Postdoctoral fellowship at Cornell University in the U.S.A. with John McMurry he joined the GSK heritage company, the Wellcome Foundation and over the next 15 years contributed to and led drug discovery projects in Wellcome and GlaxoWellcome in Pesticides, Immunology, Virology and Oncology. Over this time, he and his team were responsible for the identification of 4 clinical candidates. His key achievement was leading the erbB2 Oncology Project Team that discovered Tykerb™, Stuart is a named inventor of Tykerb™. In December 2000, Stuart joined Arrow Therapeutics as Head of Chemistry and subsequently as Research Director helped build an Antiviral Drug Discovery Company that produced numerous clinical candidates. Key achievements were two clinical Proofs of Concept involving novel approaches to the treatment of Respiratory Syncytial Virus and Hepatitis C Virus infection. Arrow Therapeutics was sold to AstraZeneca in 2007 and Stuart remained as Head of Arrow until AstraZeneca closed the Arrow site at the end of 2010. In addition to his University responsibilities, Stuart is a co-founder, Director and Chief Scientific Officer of an Antiviral Drug discovery company, re:VIRAL Ltd, founded in 2011. He is Principal Investigator on a Wellcome Trust funded Project, on behalf of re:VIRAL and an author of over 70 papers, patents and book chapters.
Research Interest
Filling the Void Special Interest Group
Publications
-
Chapman, J, Abbott, E, Alber, DG Baxter, RC Bithell, SK Henderson, EA Carter, MC Chambers, P Chubb, A Cockerill, GS, Collins, PL, Dowdell, VCL Keegan, SJ Kelsey, RD, Lockyer, MJ, Luongo, C, Najarro, P, Pickles, RJ, Simmonds, M Taylor, D, Tyms, S, Wilson, L.J & Powell, K.L (2007). RSV604, a novel inhibitor of respiratory syncytial virus replication. Antimicrobial Agents and Chemotherapy 51(9): 3346-3353.
-
Henderson, EA, Alber, DG, Baxter, RC, Bithell, SK, Budworth, J, Carter, MC, Chubb, A, Cockerill, GS, Dowdell, VCL, Fraser, IJ, Harris, RA, Keegan, S, Kelsey, RD, Lumley, JA, Stables, JN, Weerasekera, N Wilson, LJ & Powell, KL (2007). 1,4-Benzodiazepines as Inhibitors of Respiratory Syncytial Virus. The Identification of a Clinical Candidate. Journal of Medicinal Chemistry 50(7): 1685-1692.
-
Angell, R.M, Angell, T.D, Bamborough, P, Bamford, M.J, Chung, C-W, Cockerill, G.S, Flack, S.S, Jones, K.L, Laine, D.I, Longstaff, T, Ludbrook, S, Pearson, R, Smith, K.J, Smee, P.A, Somers, D.O & Walker, A.L (2008). Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes. Bioorganic & Medicinal Chemistry Letters 18(15): 4433-4437.
